- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07939295
Gene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical Study (KL002)
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of KL002 Injection in the Striatal Putamen Region for Patients With Mid-to-Late Stage Primary Parkinson's Disease
Evaluate the safety and tolerability of stereotactic injection of KL002 into the putamen of patients with advanced primary PD.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is an open-label, non-randomized, phase 1/2a single ascending dose study, consisting of Dose Escalation and Dose Expansion parts, to evaluate the safety, tolerability, and efficacy of KL002 in patients with advanced primary Parkinson's disease. Eligible subjects will enter the dose escalation part of the study, receive a single stereotactic intraputaminal administration of KL002, and be followed for 52 weeks in the core study and up to 5 years total in long-term follow-up (LTFU)with safety and efficacy assessments.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: jun Liu, Professor, Chief Physician, MD, Ph D
- Telefonnummer: +86-021-64370045
- E-mail: jly0520@hotmail.com
Studiesteder
-
-
-
Shanghai, Kina, 200025
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
-
Kontakt:
- Jun Liu, Professor, Chief Physician, MD, Ph D
- Telefonnummer: +86-021-64370045
- E-mail: jly0520@hotmail.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Clinically diagnosed primary PD
- Males or females ≥ 40 and ≤ 75 years old
- History of Parkinson's disease diagnosis ≥ 5 years
- Regularly take stable equivalent doses of dopaminergic drugs (including levodopa) for at least 4 weeks before the screening period
- Good compliance and regular follow-up
Exclusion Criteria:
- Atypical or secondary Parkinson's syndrome
- Have surgical contraindications or have undergone brain surgery in the past
- Any indications of elevated intracranial pressure evaluated by investigator
- Abnormal liver and kidney function
- Prior severe allergic reactions or allergic to contrast agents or unable to accept surgical anesthesia
- Any type of prior gene or cell therapy
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: low dose group
Putamen stereotactic injection of low dose of KL002 |
KL002 is a recombinant adeno-associated virus (rAAV9) vector carrying TH, GCH1, and AADC genes |
|
Eksperimentel: high dose group
Putamen stereotactic injection of high dose of KL002 |
KL002 is a recombinant adeno-associated virus (rAAV9) vector carrying TH, GCH1, and AADC genes |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Adverse event (AE) incidence
Tidsramme: From administration of KL002 to the end of the follow-up within 52 weeks
|
To evaluate AEs by CTCAE 6.0 |
From administration of KL002 to the end of the follow-up within 52 weeks
|
|
The incidence rate of DLT events
Tidsramme: within 4 weeks
|
Determined by the Safety Data Review Committee |
within 4 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Assessment of motor function
Tidsramme: within 52 weeks
|
Determined by MDS-UPDRS III. The highest score is 56 points, and the lower the score, the better the recovery situation. |
within 52 weeks
|
|
Assessment of dyskinesia
Tidsramme: within 52 weeks
|
Determined by UDysRS. The highest score is 104 points, and the lower the score, the better the recovery situation. |
within 52 weeks
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- KL002-002
- KL002 (Registry Identifier: KL002)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .